Oxodil

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxodil

Property Description
Active ingredient Formoterol fumarate dihydrate
Form Inhalation powder (DPI)
Pharmacological class Long-Acting Beta Agonist (LABA)
General purpose Sustained airway dilation
Origin Synthetic compound

What is Oxodil and What Type of Drug is Formoterol?

Oxodil is a prescription-only medicinal preparation that contains the active substance Formoterol fumarate dihydrate, which is a synthetic chemical compound used primarily to manage symptoms related to obstructed air passages. Formoterol is fundamentally classified as a bronchodilator and belongs to the pharmacological class of selective Beta-2 adrenergic receptor agonists. This medication is specifically recognized as a Long-Acting Beta Agonist (LABA), characterized by a sustained therapeutic effect on the airways for approximately 12 hours. These drugs are clinically recognized for promoting relaxation in the smooth muscles of the airways, which improves respiratory function. The medicine is designed to help keep breathing passages open over an extended period.


What is the Physical Form and Composition of Oxodil?

The physical dosage form of Oxodil is an inhalation powder, which is the required preparation for the inhalation route of administration to ensure the medicine reaches the bronchial tubes directly. The powder consists of the active substance, Formoterol, blended with an inactive carrier, generally lactose monohydrate, which ensures accurate dosing and efficient transport of the medicine during inhalation. This localized delivery method is a differentiating factor, as it bypasses the systemic effects associated with oral delivery and facilitates a rapid action on the target tissue. Oxodil is typically supplied as a single-ingredient product, focusing exclusively on the bronchodilating action of Formoterol.


What is the General Purpose of This Long-Acting Bronchodilator?

The general purpose of this medication is to provide sustained maintenance relief by relaxing the constricted muscles that surround the air passages. The core benefit of Formoterol is that it causes effective and lasting airway dilation. This mechanism provides a functional advantage, helping to maintain open breathing passages over many hours, which is the essential role of a LABA in the long-term management of chronic conditions involving airway constriction.

Regulatory References

  1. Formoterol Oral Inhalation: MedlinePlus Drug Information

What side effects are possible with Oxodil?

Possible Side Effects and Safety Information

The safety profile of Oxodil, which contains Formoterol, a Long-Acting Beta Agonist (LABA), is formally documented in government regulatory sources, classifying potential adverse reactions by frequency and organ system.

Classification of Adverse Reactions

Adverse reactions are classified into categories based on frequency observed in regulatory studies, affecting primarily the nervous, cardiac, and musculoskeletal systems.

System Organ Class Common Reactions (ge 1/100 to < 1/10) Uncommon Reactions (ge 1/1,000 to < 1/100)
Nervous System Headache, Tremor, Dizziness Nervousness, Agitation
Cardiac Disorders Palpitations, Tachycardia (fast heart rate) Cardiac arrhythmias
Metabolism & Nutrition Hyperglycemia, Hypokalemia
Infections Nasopharyngitis, Upper respiratory tract infection

Commonly reported effects also include Insomnia, Dry mouth, Diarrhea, and Muscle spasms. Less frequently, reactions involving Hyperglycemia (high blood sugar) and Hypokalemia (low potassium) are documented metabolic effects.

Serious Adverse Reactions and Safety Constraints

The most serious documented safety concerns include the risk of Paradoxical Bronchospasm, which is an immediate, severe increase in breathing difficulty following inhalation. Additionally, official labeling notes that the use of any LABA, including Formoterol, as monotherapy for asthma is associated with an increased risk of serious asthma-related events, including death and hospitalization, representing a regulatory constraint on use. Serious hypersensitivity reactions, such as Anaphylaxis and Angioedema, are also noted in official safety data.

Population and Contextual Safety Notes

Caution is warranted for older adults, who may be more susceptible to cardiovascular effects. Individuals with severe hepatic impairment may experience increased systemic exposure. Furthermore, regulatory documents cite that concomitant use with certain medicines, such as MAOIs or Tricyclic Antidepressants, may potentiate effects on the cardiovascular system.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Formoterol (Oxodil) is officially documented as an exaggeration of the known pharmacological effects of beta2-adrenergic stimulation, as stated in regulatory labeling. The core risk lies in severe, systemic escalation of these effects, necessitating immediate medical attention.


Documented Overdose Manifestations

Official prescribing information lists signs and symptoms stemming from excessive beta-adrenergic stimulation, including:

  • Cardiovascular Effects: Tachycardia (rapid heart rate, which may reach 200 beats/ min), palpitations, cardiac arrhythmias, angina, and hypertension or hypotension.
  • Metabolic Effects: Hypokalemia (low serum potassium levels), hyperglycemia (elevated blood glucose), and metabolic acidosis.
  • Neurological Effects: Tremor, nervousness, headache, dizziness, and seizures.

Required Emergency Actions and Monitoring

Regulatory documentation classifies this event as potentially serious, with an association with cardiac arrest and fatalities reported from excessive use of inhaled sympathomimetics. Therefore, immediate medical attention is mandated if an overdose is suspected.

Treatment requires the immediate discontinuation of the drug and the institution of appropriate symptomatic and supportive therapy. No specific antidote is known, although a cardioselective beta-receptor blocker may be considered with caution due to the risk of inducing bronchospasm. Cardiac monitoring is recommended for all overdose cases.

Therapeutic Uses of Oxodil

What Oxodil Treats: Main Uses and Benefits

Oxodil is commonly used across conditions presenting with acute episodes related to respiratory function. The core benefit of this preparation is providing support that helps ease the overall symptom burden of certain distressing symptoms like bronchospasm (sudden narrowing of the airways).


Quick Fact: Supports with Shortness of Breath

Managing Acute Symptom Discomfort and Distress

This medication is generally applied in clinical settings that involve acute or unstable symptom patterns and is used when groups of symptoms, such as shortness of breath, appear suddenly or fluctuate. It offers symptomatic relief that supports patients during difficult episodes, assisting with the temporary stabilization of functional stability.

Support for Episodic and Fluctuating Symptom Patterns

Oxodil is considered relevant in conditions characterized by periods of heightened symptoms, such as Chronic Obstructive Pulmonary Disease (COPD), which involves episodic or fluctuating manifestations. It contributes to improved day-to-day comfort during symptomatic periods, helping patients cope more steadily with symptom fluctuations.

Targeting Symptoms That Cause Temporary Functional Strain

The therapeutic use is focused on managing symptoms associated with acute or episodic changes. The medicine may assist with managing symptoms that create noticeable functional strain and interfere with routine activities. It is applied across domains where short-term symptomatic assistance is appropriate, particularly when symptoms related to physical discomfort become momentarily overwhelming.

“The medicine may assist with managing symptoms that create noticeable functional strain and interfere with routine activities.”

Regulatory References

  1. Polish Medicinal Products Registry

Eligibility and Restrictions for Use

Who Can and Cannot Use Oxodil?

The population eligibility for Oxodil (Formoterol fumarate dihydrate) is strictly defined by regulatory guidelines. Use is established for Adults and Adolescents (12 years and older) for long-term maintenance treatment, but is not established for children under 6 years of age.


Absolute Contraindications (Must Not Use)

  • Asthma Monotherapy: The medicine is strictly contraindicated for patients with asthma who are not using a concomitant long-term asthma control medication (e.g., an inhaled corticosteroid).
  • Acute Symptoms: Oxodil is not indicated for the relief of acute bronchospasm or sudden, acutely deteriorating disease states.
  • Hypersensitivity: Patients with known hypersensitivity to the active substance or excipients, including those with rare hereditary lactose intolerance disorders, must not use the medicine.

Restricted and Conditional Use

  • Use requires caution in patients with certain pre-existing cardiovascular disorders (such as arrhythmias or hypertension) or metabolic conditions (such as diabetes mellitus).
  • Patients with severe hepatic or renal impairment may only use the medicine under close monitoring, and only if the documented benefit is assessed to outweigh the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Oxodil (Formoterol fumarate dihydrate) has officially documented interaction patterns that are classified primarily based on pharmacodynamic and pharmacokinetic effects. The interaction profile dictates constraints on co-administration to mitigate additive risks and therapeutic antagonism.


Prohibitions and Pharmacodynamic Risks

  • Co-administration with other Long-Acting Beta Agonists (LABAs) is formally prohibited due to the risk of additive effects that could lead to serious cardiovascular consequences.
  • Beta-adrenergic blockers (beta-blockers) may block the intended bronchodilatory effects of Formoterol and carry a documented risk of precipitating severe bronchospasm.
  • Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), and drugs that prolong the QTc interval may potentiate cardiovascular effects, increasing the risk of ventricular arrhythmias or other adverse outcomes.
  • Non-potassium-sparing Diuretics, Xanthine Derivatives, and Steroids may potentiate the hypokalemic effect associated with beta2-agonists, potentially leading to ECG changes.

Metabolic and Clearance Considerations

Formoterol is metabolized by Cytochrome P450 isoenzymes CYP2D6, CYP2C19, and CYP2C9. Inhibitors of these enzymes may reduce Formoterol clearance, potentially resulting in increased systemic exposure. This potential for reduced clearance is also a documented concern for patients with severe hepatic impairment, where heightened exposure is expected.

Mechanism of Action

Receptor-Mediated Signaling Modulation

Oxodil exerts its primary effect via interaction with G-protein coupled receptors (GPCRs) located on airway smooth muscle cells. The compound functions as an agonist, binding to these receptors to initiate an intracellular signaling sequence. This process leads to the activation of adenylyl cyclase, driving the conversion of adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP), which is a key second messenger.


Enzyme-Targeted Cascade Adjustment

Beyond receptor agonism, the molecule modifies the pathway by acting as an inhibitor of phosphodiesterase (PDE) enzymes. By reducing the rate at which PDE degrades cAMP, Oxodil ensures the sustained elevation of specific intracellular second messenger concentrations. This dual-pathway effect modulates kinase activity, ultimately resulting in the phosphorylation of contractile proteins within the smooth muscle cell.


Local Physiologic Response Regulation

The resulting molecular actions collectively lead to relaxation of the bronchial smooth muscle, which is the physiological consequence of reduced intracellular calcium and protein phosphorylation. This modulation of smooth muscle contractility decreases resistance to respiratory gas exchange within the pulmonary system.

Dosage and Administration Information

Oxodil, which contains Formoterol fumarate dihydrate, is administered solely via Oral Inhalation using a specific dry powder inhaler (DPI) device. The medicine is provided as an inhalation powder in capsules that must not be swallowed, but rather placed into the designated inhaler for proper delivery into the airways.

Official Dosing and Frequency

Administration Scope Standard Regimen (Label-Based)
Route of Administration Oral Inhalation
Maintenance Dosing (Adults ge 18) 12 mcg per administration
Maintenance Frequency Twice daily (every 12 hours, morning and evening)
Maximum Daily Dose 24 mcg
Pediatric Use 12 mcg (Age ge 5 years, for maintenance or EIB prevention)
EIB Prevention 12 mcg at least 15 minutes before exercise (as needed)

Procedural Constraints

This medicine is for long-term, scheduled use and is not indicated for the immediate relief of acute breathing symptoms or acute bronchospasm. It must not be used in conjunction with any other long-acting beta-agonist (LABA), and the maximum daily dose is not to be exceeded. If a maintenance dose is missed, the protocol is to skip that dose and take the next scheduled dose at the usual time, without doubling the amount. These constraints define the appropriate protocol for using this scheduled bronchodilator.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Oxodil (Formoterol)


Evidence Base for Chronic Obstructive Pulmonary Disease (COPD)

The research for Formoterol in Chronic Obstructive Pulmonary Disease (COPD) includes numerous Randomized Controlled Trials (RCTs) and comprehensive Meta-analyses. The studies explored outcomes related to fluctuating or unstable symptoms and compared Formoterol against inactive treatments (placebo) or standard bronchodilators. Researchers examined functional measures of the lungs, specifically the Forced Expiratory Volume in 1 second ( FEV1), as well as patient-reported outcomes describing perceived discomfort. Studies monitored patients for long-term observations extending up to one year. Findings describe patterns observed related to FEV1 measurements and documented outcomes related to episodic or acute changes, such as the frequency of exacerbations (sudden, severe symptom worsening).


Research for Persistent Asthma (Use in Combination Only)

Research exploring Formoterol's use for persistent asthma is based on Randomized Controlled Trials (RCTs), but these trials were specifically designed to study Formoterol only when it was combined with an inhaled corticosteroid (ICS). The trials documented symptoms in conditions characterized by fluctuating or episodic manifestations, focusing on both lung function and the frequency of severe asthma events. The findings describe patterns observed related to measurements of lung function in the required combination context. Research has also explored outcomes related to prophylaxis (prevention) of symptoms induced by physical exercise. The research base does not support or characterize the use of Formoterol as a single-agent treatment (monotherapy) for persistent asthma; regulatory findings noted patterns of serious asthma-related events when the drug was used without a concomitant ICS.


Areas of Research Uncertainty and Study Gaps

Evidence is considered limited in several key areas. For instance, comparative research for direct, head-to-head comparisons against every available bronchodilator is limited. Additionally, certainty remains low regarding the effects of long-term use (beyond one year) on certain patient-reported outcomes describing perceived discomfort. Overall, the follow-up durations were limited in many of the shorter trials. Findings describe group patterns, not personal outcomes, and evidence highlights what is known—and what is still uncertain.

Key Studies & References

  1. FDA Updates SYMBICORT Label With LABA Safety Class Revisions and Removes Boxed WARNING for Serious Asthma-Related Outcomes
  2. Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease

Frequently Asked Questions (FAQ)

Common questions about Oxodil (FAQ)

Q: Does Oxodil cause any long-term effects that people should know about?

A: Official regulatory documents indicate that the use of this class of medicine (Long-Acting Beta Agonists or LABAs) as a single treatment for asthma is associated with an increased risk of serious asthma-related events, which includes hospitalizations and death. Regulatory documents also indicate that caution is warranted for older adults due to the potential for increased susceptibility to cardiovascular effects.

Q: Is Oxodil safe to use for older adults?

A: According to official product information, the use of Oxodil in the older adult population requires caution. This is described because individuals in this age group may be more susceptible to the potential cardiovascular effects of the drug.

Q: Can Oxodil affect the results of blood tests?

A: Official labeling states that the medicine can cause specific changes in the body’s chemistry, notably Hyperglycemia (high blood sugar) and Hypokalemia (low potassium). These effects mean that professional monitoring of blood work may be considered by a healthcare provider.

Q: What condition is Oxodil officially approved to treat?

A: Regulatory documents state that official indications for this medicine include the long-term maintenance treatment of obstructed airways in patients with Chronic Obstructive Pulmonary Disease (COPD). It is also approved for use in asthma, but only when used alongside another long-term asthma control medication, such as an inhaled corticosteroid.

Q: Has Oxodil been recalled or received any black box warnings?

A: The class of medicines that Oxodil belongs to (LABAs) carries an FDA-mandated Boxed Warning regarding the risk of serious asthma-related events. This prominent warning is a required feature of the official labeling and highlights the risk of death or hospitalization when the drug is used alone as a treatment for asthma.

Q: Are there different strengths of Oxodil tablets available?

A: Official regulatory documentation generally supplies the medicine as an inhalation powder capsule in a single strength of 12 micrograms. It is not supplied as an oral tablet.

Q: Can someone take Oxodil if they are already taking multiple medications?

A: Official regulatory information advises that a patient should inform their healthcare provider about all other medicines they are currently using. Taking multiple medicines requires a professional assessment is needed to determine the overall interaction profile.

Q: Does Oxodil interact with other common mental health medications?

A: Yes, official drug information indicates interactions with specific mental health drug classes, including Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs). Some data suggest a need for caution when the drug is combined with certain Selective Serotonin Reuptake Inhibitors (SSRIs) due to the potential for effects on heart rhythm.

Q: How quickly should someone expect to feel the effects of Oxodil?

A: Studies and official information indicate that this medicine has a rapid onset of action. Bronchodilation, the opening of the airways, has been observed to begin within two to three minutes after proper inhalation.

Q: Does Oxodil interact with any common herbal supplements?

A: Regulatory guidelines advise that healthcare providers should be informed about all medications, including vitamins and herbal supplements. Regulatory documents state that informing a healthcare provider of all substances is advised for a complete review of potential interactions.

Q: What happens if you stop taking Oxodil suddenly?

A: Official documentation describes that the drug is not intended to be stopped without the professional oversight of a healthcare provider. Because it is a maintenance treatment for chronic conditions, discontinuing the drug suddenly may cause breathing problems to worsen or return.

Q: Is Oxodil known to cause weight gain?

A: Review of the official regulatory documentation indicates that weight gain is not listed as a common or uncommon side effect observed in clinical trials.

Q: Can Oxodil be used during pregnancy or while breastfeeding, according to official guidelines?

A: Regulatory documents describe that the use of the drug during pregnancy is considered when the potential benefit is assessed to justify the potential risk to the fetus. When administered to a nursing woman, caution is advised because the active substance may be excreted into human milk.

Q: Are there any specific foods or drinks that should be avoided while taking Oxodil?

A: Official regulatory information does not list mandatory food restrictions. However, some data mention the potential for interactions with substances like Grapefruit Juice that could affect how the medicine works. Specific consumption instructions are best clarified by a healthcare provider.

Q: How is the safety of Oxodil monitored by health agencies?

A: The safety of Oxodil is monitored by health agencies through a system of continuous review. This includes analyzing the data collected during initial clinical trials and through subsequent post-marketing surveillance, which is the reporting system for adverse events after the drug has been made available to the public.

Q: What is the risk of dependence or addiction with Oxodil?

A: According to official documentation, the active ingredient in Oxodil is not listed as a controlled substance. It is not associated with a risk of dependence or addiction.

Q: Is there a generic version of Oxodil available?

A: The active ingredient, Formoterol fumarate dihydrate, is available from various manufacturers. It is available either in generic forms or as a component in other brand-name combination products.

Q: How long does Oxodil typically stay in the body?

A: According to regulatory pharmacokinetic studies, the drug is gradually removed from the body over time. The terminal elimination half-life of the drug is determined to be approximately 10 hours after inhalation.

Q: What if Oxodil doesn't seem to be working after a few weeks?

A: Official warnings state that a decrease in drug effectiveness may signal a deterioration of the underlying disease. Regulatory guidance describes that a worsening of symptoms requires an immediate professional re-evaluation of the patient’s condition and treatment regimen.

Q: Does alcohol change the way Oxodil works?

A: Official drug information generally advises caution regarding the use of alcohol due to the potential for interaction. However, a specific prohibition against consumption is not listed universally in the primary regulatory label.

Q: Can Oxodil make a person feel tired or sleepy?

A: Regulatory trial data lists fatigue as a common adverse reaction that has been observed. However, the specific terms sleepiness or somnolence are not typically listed among the most frequently reported effects.

Q: Does Oxodil affect mental alertness or the ability to drive?

A: Some common side effects, such as headache, dizziness, tremor, nervousness, and insomnia, may potentially affect a person's alertness. Because of these potential effects, professional guidance notes that caution may be necessary when performing skilled tasks like driving or operating machinery.

Q: What should be done if someone experiences a severe headache after taking Oxodil?

A: A headache is listed as a common side effect in official documentation. Regulatory guidelines state that for any reaction that is severe, concerning, or persistent, reporting the suspected adverse reaction to a healthcare provider is necessary.

Q: Does Oxodil interact with caffeine?

A: Yes, regulatory data indicates that there is a moderate interaction risk when Oxodil is used with caffeine. Both substances can increase heart rate and blood pressure, and using them together may enhance these cardiovascular effects.

Q: Can Oxodil be taken with or without food?

A: Official administration instructions for the inhalation powder or solution do not specify a restriction regarding taking the dose with or without food. The medicine is inhaled directly into the lungs.

Q: What information is provided on the official patient information leaflet for Oxodil?

A: Official labeling includes a dedicated Patient Counseling Information section. This section outlines key safety risks, instructions on how to properly use the medication and inhaler device, and what to do in case of an acute worsening of symptoms.

Q: Are there any lifestyle changes that official documents suggest while taking Oxodil?

A: Regulatory documents suggest caution for individuals with certain coexisting medical conditions, such as diabetes or cardiovascular disorders. Official guidance may include the need for monitoring blood sugar or potassium levels for individuals with these coexisting medical conditions.

Q: What happens if a pregnant person accidentally took Oxodil?

A: Official documentation describes the need for the patient to contact a healthcare provider promptly, as the drug may have effects related to uterine contractility during labor and delivery.

Q: What kind of professional is typically consulted for a prescription of Oxodil?

A: Since the drug is indicated for the treatment of chronic respiratory conditions like COPD and asthma, it is typically prescribed by a healthcare provider specialized in respiratory or pulmonary medicine.

How should Oxodil be stored and disposed of?

How to Store and Dispose of Oxodil

Official regulatory guidelines strictly define the storage and disposal of Oxodil (formoterol inhalation powder) to maintain its stability and effectiveness.

Storage Requirements

Condition Requirement
Temperature Store at or below 25 C to 30 C (Controlled Room Temperature).
Protection Must be stored in a cool dry place and protected from moisture.
Container Keep in the original container (blister or device); capsules must be removed immediately before use.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

  • Unused/Expired Product: Must be returned to a pharmacist or designated take-back program for proper disposal.
  • Environmental Handling: Disposal must follow local environmental regulations and must not be discarded into household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oxodil found in:

A-Z Index: